Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma

Blood

Volumn 124, Issue 13, 2014, Pages 2072-2080

  El Hajj, Hiba ^a   Khalil, Bariaa ^a   Ghandour, Botheina ^a   Nasr, Rihab ^a   Shahine, Sharif ^a   Ghantous, Akram ^a   Abdel Samad, Rana ^a   Sinjab, Ansam ^a   Hasegawa, Hideki ^b   Jabbour, Mark ^a   Hall, William W ^c   Zaatari, Ghazi ^a   Dbaibo, Ghassan ^a   Pisano, Claudio ^d   Bazarbachi, Ali ^a   Darwiche, Nadine ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d Grande Ospedale Metropolitano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAROTENE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN P21; PROTEIN P53; TAX PROTEIN; 3-(4'-HYDROXY-3'-ADAMANTYLBIPHENYL-4-YL)ACRYLIC ACID; ADAMANTANE; ANTINEOPLASTIC AGENT; CASPASE; CINNAMIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL INFILTRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA DAMAGE; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOBLOTTING; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PROTEIN CLEAVAGE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN SIZE; T CELL LEUKEMIA; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LEUKEMIC INFILTRATION; METABOLISM; MORTALITY; PATHOLOGY; TRANSFORMED CELL LINE; TUMOR CELL LINE;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CINNAMATES; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE PRODUCTS, TAX; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LEUKEMIC INFILTRATION; MICE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907270630     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-560060     Document Type: Article

References (51)

1. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5(11):664-672.
2. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280.
3. Gallo RC. Research and discovery of the first human cancer virus, HTLV-1. Best Pract Res Clin Haematol. 2011;24(4):559-565.
4. Kfoury Y, Nasr R, Hermine O, de Thé H, Bazarbachi A. Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway. Cell Death Differ. 2005;12(Suppl 1):871-877.
5. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736-1745.
6. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T cell leukaemia: a review of established and new treatments. BioDrugs. 1998;10(6):447-462.
7. Mahieux R, Watanabe T. Forefront studies on HTLV-1 oncogenesis. Front Microbiol. 2013;4:156.
8. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemialymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453-459.
9. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Suppl 1):S186-S190.
10. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177-4183.
11. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744-1748.
12. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749-1751.
13. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26):6528-6532.
14. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20(49):7140-7145.
15. Fenaux P, Chastang C, Chevret S, et al The European APL Group. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-1200.
16. Miyatake JI, Maeda Y. Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia cells. Leukemia. 1997;11(3):401-407.
17. Darwiche N, Hatoum A, Dbaibo G, et al. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. Leukemia. 2004;18(3):607-615.
18. Maeda Y, Miyatake J, Sono H, et al. New therapeutic effects of retinoid for adult T-cell leukemia. Blood. 1996;88(12):4726-4727.
19. Maeda Y, Yamaguchi T, Hijikata Y, et al. Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol. 2008;134(6):673-677.
20. de Thé H. Altered retinoic acid receptors. FASEB J. 1996;10(9):955-960.
21. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia. 2002;16(4):463-472.
22. Bernard BA, Bernardon JM, Delescluse C, et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992;186(2):977-983.
23. Cincinelli R, Dallavalle S, Merlini L, et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem. 2003;46(6):909-912.
24. Garattini E, Parrella E, Diomede L, et al. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004;103(1):194-207.
25. Sala F, Zucchetti M, Bagnati R, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3118-3126.
26. Valli C, Paroni G, Di Francesco AM, et al. Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity. Mol Cancer Ther. 2008;7(9):2941-2954.
27. Darwiche N, El-Sabban M, Bazzi R, et al. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J. 2001;2(2):127-135.
28. Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12(4):466-472.
29. El Hajj H, El-Sabban M, Hasegawa H, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207(13):2785-2792.
30. Bitar N, Hajj HE, Houmani Z, et al. Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion. 2009;49(9):1859-1864.
31. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol. 1990;10(10):5502-5509.
32. Dbaibo GS, Pushkareva MY, Rachid RA, et al. p53-dependent ceramide response to genotoxic stress. J Clin Invest. 1998;102(2):329-339.
33. Fratelli M, Fisher JN, Paroni G, et al. New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: the role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome. Eur J Cancer. 2013;49(6):1491-1500.
34. Zuco V, Zanchi C, Lanzi C, et al. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response. Neoplasia. 2005;7(7):667-677.
35. Wang Q, Cui K, Espin-Garcia O, et al. Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis. PLoS ONE. 2013;8(12):e82363.
36. Yu T, MacPhail SH, Banáth JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst). 2006;5(8):935-946.
37. Nakamura AJ, Redon CE, Bonner WM, Sedelnikova OA. Telomere-dependent and telomere-independent origins of endogenous DNA damage in tumor cells. Aging (Albany, NY Online). 2009;1(2):212-218.
38. Baydoun HH, Bai XT, Shelton S, Nicot C. HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ. PLoS ONE. 2012;7(8):e42226.
39. Hall AP, Irvine J, Blyth K, Cameron ER, Onions DE, Campbell ME. Tumours derived from HTLV-I tax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. J Pathol. 1998;186(2):209-214.
40. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax downregulation and reversal of NF-kappa B activation. Blood. 2000;96(8):2849-2855.
41. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101(11):4576-4582.
42. Parrella E, Giannì M, Fratelli M, et al. Antitumor activity of the retinoid-related molecules (E)-3-(4′-hydroxy-3′-adamantylbiphenyl-4-yl) acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways. Mol Pharmacol. 2006;70(3):909-924.
43. Mahieux R, Pise-Masison CA, Lambert PF, et al. Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function. J Virol. 2000;74(15):6866-6874.
44. Mahieux R, Pise-Masison CA, Nicot C, Green P, Hall WW, Brady JN. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses. 2000;16(16):1677-1681.
45. Pise-Masison CA, Mahieux R, Jiang H, et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol. 2000;20(10):3377-3386.
46. Bargonetti J, Reynisdóttir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 1992;6(10):1886-1898.
47. Pisano C, Vesci L, Foderà R, et al. Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models. Ann Oncol. 2007;18(9):1500-1505.
48. Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014;20(2):167-174.
49. Zhao T, Satou Y, Matsuoka M. Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice. Arch Virol. 2014;159(7):1849-1856.
50. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006;103(3):720-725.
51. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93(1):278-283.